Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

MCKINNEY, Texas, March 18, 2024 /PRNewswire/ -- Globe Life Inc. (NYSE: GL) announced that its Board of Directors has raised the quarterly dividend to $.2400 per share on all of the outstanding common stock of the Company held of record as of close of business of the Company's transfer agent on April 5, 2024. The dividend will be paid on May 1, 2024. Globe Life Inc. is a holding company specializing in life and supplemental health insurance for the middle-income market distributed through multiple channels, ...

Globe Life Inc. (GL) has been gaining momentum on the back of higher life and health sales, improved invested assets, increased productivity and agent count, strong liquidity position and effective capital deployment.Earnings EstimateThe Zacks Consensus Estimate for Globe Life’s 2024 earnings per share (EPS) is pegged at $11.57, indicating an increase of 8.6% on 5.5% higher revenues of $5.82 billion. The Zacks Consensus Estimate for GL’s 2025 EPS is pegged at $12.50, indicating a year-over-year increase of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) [ ☒ ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or [ ☐ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-08052 GLOBE LIFE INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation o ...

Globe Life Inc. (NYSE:GL) Q4 2023 Earnings Conference Call February 8, 2024 11:00 AM ET Company Participants Stephen Mota – Senior Director of Investor Relations Frank Svoboda – Co-Chief Executive Officer Matt Darden – Co-Chief Executive Officer Tom Kalmbach – Chief Financial Officer Conference Call Participants Jimmy Bhullar – JP Morgan John Barnidge – Piper Sandler Ryan Krueger – KBW Suneet Kamath – Jefferies Wilma Burdis – Raymond James Tom Gallagher – Evercore ISI Operator Hello, and welcome to Globe Li ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ________ Commission File Number: 001-08052 GLOBE LIFE INC. (Exact name of registrant as specified in its charter) (State or oth ...

Globe Life Inc. (NYSE:GL) Q3 2023 Earnings Conference Call October 26, 2023 11:00 AM ET Company Participants Stephen Mota – Senior Director, Investor Relations Frank Svoboda – Co-Chief Executive Officer Matt Darden – Co-Chief Executive Officer Tom Kalmbach – Chief Financial Officer Conference Call Participants Wes Carmichael – Wells Fargo Jimmy Bhullar – JPMorgan Wilma Burdis – Raymond James Ryan Krueger – KBW Maxwell Fritscher – Truist Securities Tom Gallagher – Evercore ISI Suneet Kamath – Jefferies Opera ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: (Exact name of registrant as ...

Financial Data and Key Metrics - Net income for Q2 2023 was $215 million, or $2.24 per share, compared to $224 million, or $2.26 per share a year ago [35] - Net operating income for Q2 2023 was $251 million, or $2.61 per share, an increase of 3% from a year ago [35] - Return on equity (ROE) on a GAAP basis was 22.4%, and book value per share was $41.44 [22] - Excluding AOCI, ROE was 14.6%, and book value per share was $72.09, up 10% from a year ago [22] - Net investment income for Q2 2023 was $261 million, up 7% from a year ago, driven by higher yields on fixed maturities and short-term investments [54] Business Line Data and Key Metrics - Life insurance premium revenue for Q2 2023 increased 3% YoY to $782 million, with full-year growth expected at 4% [23] - Health insurance premium revenue grew 3% YoY to $329 million, with health underwriting margin up 1% to $92 million [24] - Direct-to-consumer life premiums increased 1% YoY to $249 million, while life underwriting margin declined 8% to $56 million due to higher policy obligations and acquisition expenses [27] - Liberty National life premiums increased 7% YoY to $87 million, with life underwriting margin up 2% to $28 million [61] - Family Heritage health premiums increased 8% YoY to $98 million, with health underwriting margin up 14% to $33 million [37] Market Data and Key Metrics - The average producing agent count for Q2 2023 was 10,488, up 8% YoY and 8% from Q1 2023 [26] - Liberty National's average producing agent count for Q2 2023 was 3,180, up 17% YoY [61] - Family Heritage's average producing agent count for Q2 2023 was 1,345, up 15% YoY [37] - Electronic sales in the direct-to-consumer division grew over 4% YoY, representing approximately 70% of new sales [27] Company Strategy and Industry Competition - The company is focused on maintaining target margins in the digital channel, scaling back on less profitable print media campaigns [19] - The company is investing in commercial mortgage loans and limited partnerships with debt-like characteristics, expected to produce additional yields [38] - The company is well-positioned to withstand market downturns and purchase higher-yielding securities opportunistically [62] - The company is focusing on growing its middle management count to improve agent recruiting, onboarding, and training [67] Management Commentary on Operating Environment and Future Outlook - The company expects continued excess mortality for the remainder of 2023 and into the next couple of years [15] - The company anticipates higher investment income from commercial mortgage loans and limited partnership investments, contributing to a higher midpoint of earnings guidance for 2023 [65] - The company expects net operating income per share for 2023 to be in the range of $10.37 to $10.57 [65] - The company is monitoring the impact of new Alzheimer's drugs on Medicare supplement rates and will incorporate estimates into 2024 rate increases [130] Other Important Information - The company repurchased 780,000 shares in Q2 2023 for a total cost of $84 million, with an average share price of $107.26 [44] - The company expects parent company excess cash flow for 2023 to be between $420 million and $440 million, available for shareholder returns [45] - The company's fixed maturity portfolio has a net unrealized loss position of approximately $1.6 billion, primarily due to interest rate-driven market conditions [133] Q&A Session Summary Question: Impact of First Republic Bank losses on the investment portfolio - The company took a $30 million after-tax provision for credit loss related to First Republic Bank [55] - The allowance for credit losses in the fixed maturity portfolio increased by $40 million in Q2 2023, primarily due to First Republic Bank losses [59] Question: Growth in Liberty National life sales - The growth in Liberty National life sales is primarily driven by significant double-digit agent growth, which started accelerating in the latter half of 2022 [17] Question: Impact of inflation on direct-to-consumer sales - The company noted that sales in the direct-to-consumer channel are subject to inflationary pressures, particularly on marketing and distribution costs [98] - However, electronic sales in the direct-to-consumer channel grew 4% YoY, offsetting declines in traditional print media [19] Question: Excess mortality and its impact on financials - The company is seeing continued excess mortality, though slightly less than anticipated, resulting in a $2.4 million remeasurement gain in Q2 2023 [112][122] - The company expects excess mortality to continue for the remainder of 2023 and into the next couple of years [15] Question: Impact of new Alzheimer's drugs on Medicare supplement rates - The company is monitoring the potential impact of new Alzheimer's drugs and will incorporate estimates into 2024 rate increases [130] Question: Share repurchase program and capital position - The company repurchased 780,000 shares in Q2 2023 and expects to continue share repurchases as the primary use of excess cash flows [44][46] - The company has sufficient liquidity to maintain its share repurchase program and dividend payments, even under stress test scenarios [57]

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) Commission File Number: 001-08052 GLOBE LIFE INC. (Exact name of registrant as specified in its charter) (State or other j ...